Abstract
This talk provides a summary of Abs to TNFR family members and their advances to the clinic (OX40, 4-1BB, CD27, GITR and CD40). In particular, OX40 agonists will be the focus of this talk and their effects on targeting T cells within the tumor microenvironment. Optimal dose and scheduling of OX40 agonists will also be reviewed.
| Original language | American English |
|---|---|
| State | Published - Feb 28 2020 |
Publication series
| Name | Articles, Abstracts, and Reports |
|---|